147 related articles for article (PubMed ID: 7915964)
21. Multivariate analysis of DNA ploidy, p53, c-erbB-2 proteins, EGFR, and steroid hormone receptors for prediction of poor short term prognosis in breast cancer.
Eissa S; Khalifa A; el-Gharib A; Salah N; Mohamed MK
Anticancer Res; 1997; 17(2B):1417-23. PubMed ID: 9137508
[TBL] [Abstract][Full Text] [Related]
22. Activation of c-erbB-2 and prognosis in ovarian carcinoma. Comparison with histologic type, grade, and stage.
Singleton TP; Perrone T; Oakley G; Niehans GA; Carson L; Cha SS; Strickler JG
Cancer; 1994 Mar; 73(5):1460-6. PubMed ID: 7906608
[TBL] [Abstract][Full Text] [Related]
23. The use of P53, PTEN, and C-erbB-2 to differentiate uterine serous papillary carcinoma from endometrioid endometrial carcinoma.
Macwhinnie N; Monaghan H
Int J Gynecol Cancer; 2004; 14(5):938-46. PubMed ID: 15361207
[TBL] [Abstract][Full Text] [Related]
24. p53 protein expression in human breast carcinoma: relationship to expression of epidermal growth factor receptor, c-erbB-2 protein overexpression, and oestrogen receptor.
Poller DN; Hutchings CE; Galea M; Bell JA; Nicholson RA; Elston CW; Blamey RW; Ellis IO
Br J Cancer; 1992 Sep; 66(3):583-8. PubMed ID: 1355662
[TBL] [Abstract][Full Text] [Related]
25. Prognostic significance and diagnostic value of PTEN and p53 expression in endometrial carcinoma. A retrospective clinicopathological and immunohistochemical study.
Daniilidou K; Frangou-Plemenou M; Grammatikakis J; Grigoriou O; Vitoratos N; Kondi-Pafiti A
J BUON; 2013; 18(1):195-201. PubMed ID: 23613406
[TBL] [Abstract][Full Text] [Related]
26. [Expression of P53, P63, and C-erbB-2 in endometrioid adenocarcinoma and their clinicopathological significance].
Hu WF; Liu MQ; Zhao Q
Ai Zheng; 2004 Sep; 23(9):1021-5. PubMed ID: 15363194
[TBL] [Abstract][Full Text] [Related]
27. Serous papillary adenocarcinoma of the endometrium. Analysis of proto-oncogene amplification, flow cytometry, estrogen and progesterone receptors, and immunohistochemistry.
Sasano H; Comerford J; Wilkinson DS; Schwartz A; Garrett CT
Cancer; 1990 Apr; 65(7):1545-51. PubMed ID: 1690076
[TBL] [Abstract][Full Text] [Related]
28. p53 and c-erbB-2 protein expression in breast carcinomas. An immunohistochemical study including correlations with receptor status, proliferation markers, and clinical stage in human breast cancer.
Barbareschi M; Leonardi E; Mauri FA; Serio G; Dalla Palma P
Am J Clin Pathol; 1992 Oct; 98(4):408-18. PubMed ID: 1357956
[TBL] [Abstract][Full Text] [Related]
29. Dual colour flow cytometry of p53 and c-erbB-2 expression related to DNA aneuploidy in primary and metastatic breast cancer.
Clark JS; George WD; Campbell AM
Cancer Lett; 1992 Oct; 66(3):193-200. PubMed ID: 1360329
[TBL] [Abstract][Full Text] [Related]
30. c-erbB-2 expression in primary gastric carcinomas and their metastases.
David L; Seruca R; Nesland JM; Soares P; Sansonetty F; Holm R; Børresen AL; Sobrinho-Simões M
Mod Pathol; 1992 Jul; 5(4):384-90. PubMed ID: 1353880
[TBL] [Abstract][Full Text] [Related]
31. Double immunostaining for c-erbB-2 and p53 in human stomach cancer cells.
Sasano H; Date F; Imatani A; Asaki S; Nagura H
Hum Pathol; 1993 Jun; 24(6):584-9. PubMed ID: 8099338
[TBL] [Abstract][Full Text] [Related]
32. P-glycoprotein, HER-2/neu, and mutant p53 expression in human gynecologic tumors.
Schneider J; Rubio MP; Barbazán MJ; Rodriguez-Escudero FJ; Seizinger BR; Castresana JS
J Natl Cancer Inst; 1994 Jun; 86(11):850-5. PubMed ID: 7910219
[TBL] [Abstract][Full Text] [Related]
33. Alterations of K-ras, p53, and erbB-2/neu in human lung adenocarcinomas.
Bongiorno PF; Whyte RI; Lesser EJ; Moore JH; Orringer MB; Beer DG
J Thorac Cardiovasc Surg; 1994 Feb; 107(2):590-5. PubMed ID: 7905543
[TBL] [Abstract][Full Text] [Related]
34. Overexpression of c-erbB-2 protein in gastric cancer. Its correlation with long-term survival of patients.
Uchino S; Tsuda H; Maruyama K; Kinoshita T; Sasako M; Saito T; Kobayashi M; Hirohashi S
Cancer; 1993 Dec; 72(11):3179-84. PubMed ID: 7902202
[TBL] [Abstract][Full Text] [Related]
35. Oncogene alterations in carcinomas of the uterine cervix: overexpression of the epidermal growth factor receptor is associated with poor prognosis.
Kersemaekers AM; Fleuren GJ; Kenter GG; Van den Broek LJ; Uljee SM; Hermans J; Van de Vijver MJ
Clin Cancer Res; 1999 Mar; 5(3):577-86. PubMed ID: 10100709
[TBL] [Abstract][Full Text] [Related]
36. p53 overexpression and bcl-2 persistence in endometrial carcinoma: comparison of papillary serous and endometrioid subtypes.
Zheng W; Cao P; Zheng M; Kramer EE; Godwin TA
Gynecol Oncol; 1996 May; 61(2):167-74. PubMed ID: 8626128
[TBL] [Abstract][Full Text] [Related]
37. Expression of proliferating cell nuclear antigen (PC10), p53 protein and c-erbB-2 in renal adenocarcinoma.
Lipponen P; Eskelinen M; Hietala K; Syrjänen K; Gambetta RA
Int J Cancer; 1994 Apr; 57(2):275-80. PubMed ID: 7908898
[TBL] [Abstract][Full Text] [Related]
38. Uterine papillary serous, clear cell, and poorly differentiated endometrioid carcinomas: a comparative study.
Greggi S; Mangili G; Scaffa C; Scala F; Losito S; Iodice F; Pisano C; Montoli S; Viganò R; Pirozzi G; Giannarelli D
Int J Gynecol Cancer; 2011 May; 21(4):661-7. PubMed ID: 21412164
[TBL] [Abstract][Full Text] [Related]
39. Prognostic significance of p53, PCNA, and c-erbB-2 in endometrial enocarcinoma.
Heffner HM; Freedman AN; Asirwatham JE; Lele SB
Eur J Gynaecol Oncol; 1999; 20(1):8-12. PubMed ID: 10422671
[TBL] [Abstract][Full Text] [Related]
40. A case-matched molecular comparison of extraovarian versus primary ovarian adenocarcinoma.
Kowalski LD; Kanbour AI; Price FV; Finkelstein SD; Christopherson WA; Seski JC; Naus GJ; Burnham JA; Kanbour-Shakir A; Edwards RP
Cancer; 1997 Apr; 79(8):1587-94. PubMed ID: 9118043
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
